Last week we reported that Merck's lobbying efforts to get the HPV vaccine Gardasil mandated in states across the country could backfire and actually slow the process. Yesterday, low and behold, the pharmaceutical company announced it was halting its lobbying efforts nationwide after facing a growing contingent of critics, some of whom were supporters of the vaccine itself. The misstep is particularly bitter for the drug giant as it has been enjoying overwhelmingly positive press following Gardasil's approval last June, and likely didn't need an overzealous lobbying effort to ensure it became status quo for young women around the country. It will be interesting to monitor how states considering legislation on the vaccine proceed from here.
Have you registered with us yet?
Register now to enjoy more articles and free email bulletins